Bill serves in the evaluation of chemical assets of early opportunities and is responsible for the medicinal chemistry strategies for NEOMED projects.
Bill was most recently responsible for leading multidisciplinary teams that were responsible for evaluating external opportunities for AstraZeneca, and has also led multidisciplinary project teams that have advanced two compounds into Phase II studies. Following his move to AstraZeneca in 1996, he first led medicinal chemistry projects delivering four clinical candidates. Bill started his drug discovery career in 1990 at BioChem Pharma where he led medicinal chemistry projects in the field of antiviral therapies and received the BioChem Excellence award in both 1993 and 1994.
Bill received his PhD from the University of Ottawa and did postdoctoral research at Stanford and Duke Universities. He has co-authored 35 peer-reviewed scientific publications and is an inventor on 33 patents.
Kemal brings to NEOMED deep expertise in the areas of pharmacology and overall project risk assessment. He is also a key resource in evaluating early stage projects that could be selected by NEOMED among available partnering opportunities.
Before joining NEOMED, Kemal was Director of the Montreal Discovery Portfolio at AstraZeneca since 2007. During that time, he also served on several global teams managing AstraZeneca’s Neuroscience discovery portfolio, such as the CNS/Pain Lead Optimization Projects Network, the Lead Generation Team, and the Portfolio Management Team. He had relocated to Montreal in 1994, to become one of the founding members of the Astra Pain Research Unit, where he established the In Vitro Pharmacology section. In the years following the Astra merger with Zeneca, Kemal became Director of the Molecular Pharmacology Department, and contributed to the delivery of several candidate drugs targeting various GPCRs, ion channels, and enzymes. Kemal also led several target identification and lead generation projects, served on lead optimization project teams, and contributed to the evaluation of various external project opportunities. Kemal began his professional research career in 1988 as a postdoctoral fellow at the National Institute of Health (NICHD in Bethesda, MD), where he was the recipient of an Intramural Research Training Award covering his work on the mechanism and modulation of neuro-secretion. Subsequently, as a Staff Fellow at NIMH (Washington, D.C.), he studied the in vitro pharmacology of Neuropeptide FF receptors.
Kemal earned his PhD in 1987 in Pharmacology and Therapeutics at the University of Florida, an MSc from the Marine Science Institute of Middle East Technical University in Turkey, and a BSc in Biochemistry from the State University of New York at Binghamton. He received both the New York State Regents Scholarship and the S.U.N.Y. Foundation Scholarship. He has 37 publications in peer-reviewed journals, one patent, and published a book chapter on the in vitro pharmacology of cloned human opioid receptors.
Patricia is Director, Scientific Affairs at NEOMED. She is responsible for establishing links with academic institutions in order to identify new innovative projects to help the maturation of active projects and to ensure the visibility of NEOMED with potential partners.
Before joining NEOMED, Patricia worked in the development unit of the Department of Life Sciences of the Atomic Energy Commission in France (Direction des Sciences du Vivant du Commissariat à l’Énergie Atomique), as a technology transfer officer. She then spent four years first as Project Manager and then as Project Director at Univalor, the university technology transfer organization of Université de Montréal and its affiliated health centres. In charge of a portion of the life sciences technologies portfolio, her mission was to assess the technical and commercial potential of inventions to assist in their maturation and transfer to market. As such, Patricia evaluated over 100 projects from academia by ensuring due diligence, protection of intellectual property, analysis of market potential, grant application submission for the maturation of technologies, as well as discussions and negotiations with potential partners that led to research collaborations and licensing agreements, or the creation of spin-offs. Patricia also gained substantial experience in popular science as a scientific mediator in the Palais de la Découverte scientific museum in Paris for several years.
Patricia holds a PhD in Cellular Biology from Université Pierre et Marie Curie in Paris and a Professional Master in Innovation and Commercialization of Research from Université Paris Sud.
Jean-François is responsible for the medicinal chemistry components of projects and provides expertise in project evaluation and progression at NEOMED.
Before joining NEOMED, Jean-François was Unit Manager in charge of lead optimization at Galderma, a world leader in dermatology, where he worked on multiple projects as project leader, drug designer, expert chemist for target identification/selection or research data steward. In these roles, he has implemented cheminformatics tools, created topical by design rules and contributed to three compounds evaluated in the clinic. Jean-François started his drug discovery career at Merck Frosst in 2006 where he worked as Senior Research Chemist on multiple projects aimed at oral delivery.
Jean-François received his PhD under the supervision of Professor Charette at the Université de Montréalfollowed by postdoctoral work with Professor Corey at Harvard University. He has coauthored 21 peer-reviewed scientific publications and is a coinventor on 17 patents.
Shirley is in charge of the Institute’s global communications (external communications, press relations, social media, etc.).
Before joining NEOMED, Shirley worked in Paris where she held the position of Press Officer in various communication agencies.
Graduated with a master degree in global and digital communications, from Sup de Pub – INSEEC in Paris, Shirley also holds the diploma of EFAP (French School of Press Attachés). In order to perfect her English, Shirley lived in Australia for two years.